1. Scrip
  2. >>Focus On Asia

SCARDA: Japan’s New Vaccine R&D Center With $1.6bn Budget – But Where's The Goal?

Hopes But Some Concerns

 
• By Lisa Takagi

Japan has launched a new center to support vaccine and drug projects as a part of a larger scheme to tackle infectious disease. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects.   

SCARDA will control innovative vaccine R&D projects in Japan.
SCARDA Will Control Innovative Vaccine R&D Projects In Japan • Source: Alamy

On 22 March 2022, Japan announced the establishment of a new center to support innovative R&D projects for vaccines and drugs, although there appears to be some public skepticism around the initiative.

The organization, the Strategic Center of Biomedical Advanced Research and Development for Preparedness and Response (SCARDA), will focus on innovative projects to build “the world’s top-level” development sites for vaccines and related modality

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.